ArticleBMC neurology2026
Red flags in asymmetric axonal neuropathy revealing MPO-ANCA-associated microscopic polyangiitis: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMononeuritis multiplex is a recognized, though sometimes overlooked, clinical feature of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis. When renal or pulmonary involvement is initially mild, the condition may mimic common neurological disorders and diagnosis can be delayed. CASE PRESENTATION: A 51-year-old woman presented with a five-month history of progressive bilateral lower-limb pain and edema, followed by three weeks of rapidly progressive asymmetric weakness affecting all four limbs. Nerve conduction studies showed severe multifocal axonal neuropathy with marked side-to-side compound muscle action potential asymmetry, consistent with mononeuritis multiplex. Laboratory evaluation demonstrated anemia, hypoalbuminemia, proteinuria, microscopic hematuria, MPO-ANCA positivity, and a subsequent creatinine rise from 76 to 121 μmol/L, indicating early but clinically evident systemic involvement. Chest computed tomography showed right-sided nodular/parenchymal pulmonary lesions with bilateral chronic/interstitial changes. Treatment with glucocorticoid-based induction therapy together with a documented cyclophosphamide-containing discharge regimen was associated with marked early improvement in pain, strength, inflammatory markers, and renal indices.
conclusionsThree red flags should prompt early ANCA testing in patients with rapidly progressive asymmetric axonal neuropathy: multifocal asymmetric axonal loss with relatively preserved conduction velocities on nerve conduction studies; early renal abnormalities such as hematuria, proteinuria, or rising creatinine; and concordant systemic findings including hypoalbuminemia, elevated inflammatory markers, or pulmonary imaging changes. Early recognition may allow treatment before axonal injury becomes irreversible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.